Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$54.98 USD
+0.84 (1.55%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $54.97 -0.01 (-0.02%) 7:56 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Crinetics Pharmaceuticals, Inc. [CRNX]
Reports for Purchase
Showing records 41 - 60 ( 87 total )
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Provides Encouraging Pipeline Update at ENDO2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Initiates Phase 1 Study for Oral ACTH Inhibitor; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Congenital Hyperinsulinism Program Enters the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Crinetics Presents 2021 Pipeline Development Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Five Takeaways from KOL Call That Boost Our Confidence Paltusotine Can Slay the Giant of Acromegaly
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Gearing up for Acromegaly Phase 3 and Several First-in-Human Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Paltusotine Maintains Its Edge in Additional ACROBAT Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Productive Quarter as Pipeline Advances and Paltusotine Clears First Hurdle; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Key Takeaways from HCW @ Home With Crinetics and Endo Online 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our Thoughts On This Morning''s Edge Update - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q20 - What''s Good for the Goose Is Good for the Gander
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
Additional Quick Thoughts as Paltusotine Moves Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Crinetics Pharmaceuticals, Inc.
Industry: Medical - Drugs
No Need to Wait as Paltusotine Shows Enough of an Edge to Move Into Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D